# China Dry Age Related Macular Degeneration Market > China Dry Age-Related Macular Degeneration (AMD) Market Research Report: Size, Share, Trend Analysis By Stage (Early Age-Related Macular Degeneration, Intermediate Age-Related Macular Degeneration, Late Age-Related Macular Degeneration), By Age Group (Above 75 years, Above 60 years, Above 40 years), By Diagnosis and Treatment (Treatment, Diagnosis), By Route of Administration (Oral, Injectables) and By End Userss (Hospitals Clinics, Diagnostic Centers, Academic Research Institutes) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 7.52% - **2024:** $ 357 Million - **2025:** $ 386.62 Million - **2035:** $ 792.75 Million - **Key Players:** Novartis (CH), Roche (CH), Regeneron Pharmaceuticals (US), Bayer (DE), Allergan (IE), Santen Pharmaceutical (JP), Hua Medicine (CN), Chongqing Zhifei Biological Products (CN) **Report ID:** MRFR/MED/43221-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/china-dry-age-related-macular-degeneration-market-44901 --- ## Market Summary ## **China Dry Age-Related Macular Degeneration (AMD) Market Overview** As per MRFR analysis, the China Dry Age-Related Macular Degeneration (AMD) Market Size was estimated at 330.0 (USD Million) in 2023. The China Dry Age-Related Macular Degeneration (AMD) Market Industry is expected to grow from 360.0(USD Million) in 2024 to 910.0 (USD Million) by 2035. The China Dry Age-Related Macular Degeneration (AMD) Market CAGR (growth rate) is expected to be around 8.796% during the forecast period (2025 - 2035). **Key China Dry Age-Related Macular Degeneration (AMD) Market Trends Highlighted** The China Dry Age-Related Macular Degeneration (AMD) Market is witnessing noteworthy trends driven by an aging population and increased awareness about eye health. With the Chinese population aging rapidly, there is a growing demand for effective treatments and preventative measures against AMD. The government’s healthcare initiatives are prioritizing eye care, reflecting a commitment to combat vision impairment as part of its broader public health strategy. This focus is supported by campaigns aimed at educating citizens about AMD risk factors and the importance of regular eye check-ups, thus amplifying the emphasis on early diagnosis and intervention. The market also has new opportunities resulting from improving technologies and the advancement of pharmaceuticals. There is a market opportunity in the development of new treatment alternatives, such as gene therapy or nutritional supplements. Domestic companies are now more willing to work with foreign partners in devising suitable therapeutics for the Chinese population which further deepens the market. Improving the distribution channels of ocular health products also helps these people receive the treatment they need. There is more interest in using telemedicine and online consultations for AMD patients in China because of the pandemic. This shift not only ensures continued patient care but also addresses barriers to access, particularly in rural areas where specialized eye care services may be limited. As hospitals and clinics adapt to this digital shift, there will be further integration of e-health solutions in managing AMD. Overall, the convergence of technological innovation, government support, and increased public awareness is shaping a dynamic landscape for the Dry AMD market in China. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **China Dry Age-Related Macular Degeneration (AMD) Market Drivers** **Aging Population in China Driving Market Growth** The aging population in China is a significant driver for the China Dry Age-Related Macular Degeneration (AMD) Market Industry. According to China's National Bureau of Statistics, in 2020, nearly 18% of the population was aged 60 or older, a figure expected to rise to over 34% by 2050. This demographic shift will lead to a higher prevalence of age-related diseases, including AMD, prompting increased demand for treatment options, screening procedures, and healthcare services.The growing elderly demographic will likely boost market investments from healthcare providers who need to cater to this expanding patient base. Additionally, the Ministry of Health has highlighted that the Chinese healthcare system is gearing up to manage chronic diseases tied to aging, which will further facilitate advancements and availability in the AMD market. The increasing number of elderly patients will ultimately necessitate more effective management strategies and products catered specifically for AMD. **Enhancements in Healthcare Infrastructure** Improvements in healthcare infrastructure significantly contribute to the growth of the China Dry Age-Related Macular Degeneration (AMD) Market Industry. The Chinese government has made substantial investments to enhance healthcare facilities across the nation, especially with the Healthy China 2030 plan. The plan emphasizes enhancing accessibility to medical services, which includes regular screening and early detection of age-related diseases like AMD.Over the last five years, there has been a reported 15% increase in the number of eye care clinics and hospitals due to government initiatives and support. This expansion means that more patients will have access to essential AMD treatment options, thereby increasing the market's reach and promoting customer engagement with healthcare services specifically designed to combat AMD. **Growing Awareness and Education on AMD** The increasing awareness and education about age-related eye diseases, specifically AMD, have become a critical driver for growth in the China Dry Age-Related Macular Degeneration (AMD) Market Industry. The Chinese government has launched numerous public health campaigns in collaboration with organizations such as the China Association of Ophthalmology, raising awareness about the risk factors and symptoms related to AMD. Reports from public health studies indicate that public awareness of AMD has doubled in the last decade, with over 60% of people now recognizing the condition and its related risks.As a result, more individuals are likely to seek preventive care and screening, leading to increased demand for AMD-targeted treatments and diagnostic services, ultimately benefiting the market's growth. **Innovation in AMD Treatments and Technologies** Ongoing innovation in treatments and technologies for AMD presents a compelling growth driver for the China Dry Age-Related Macular Degeneration (AMD) Market Industry. Recent advancements in pharmacological treatments, particularly the development of intravitreal injections and novel therapeutics, are sharpening their competitive edge in the medical field. The National Medical Products Administration in China has indicated a 25% increase in the approval of new ocular therapeutics over the past three years, reflecting the rapid progression in this domain.As new-generation drugs, such as anti-VEGF therapies, become more accessible and effective, healthcare providers are likely to adopt these technologies more widely, thus increasing patient treatment options and further driving market growth. **China Dry Age-Related Macular Degeneration (AMD) Market Segment Insights** **Dry Age-Related Macular Degeneration (AMD) Market Stage Insights** The China Dry Age-Related Macular Degeneration (AMD) Market, classified into the stage of disease progression, reflects a critical aspect of combating vision-related issues prevalent among the aging population in the country. This market is structured into early, intermediate, and late age-related macular degeneration stages, which collectively represent different degrees of severity and clinical intervention requirements.  The early stage serves as a precursor for potential vision loss, highlighting the importance of timely screening and detection in order to implement preventive measures or lifestyle modifications.As individuals progress to the intermediate stage, the condition may lead to noticeable vision changes, thus increasing demand for targeted therapies and management strategies tailored to those affected. The late stage, characterized by significant vision impairment, is crucial for healthcare systems, requiring advanced treatment options and possibly surgical interventions to improve patient outcomes.  With a growing elderly demographic in China, the emphasis on understanding each progression stage of Dry AMD is paramount for healthcare professionals.As a result, healthcare providers are investing in education and awareness campaigns aimed at early detection, fostering greater engagement among at-risk populations. Moreover, government health policies are increasingly focusing on funding for research and development initiatives that explore new therapeutic options and enhance patient access to necessary care.  The increasing prevalence of risk factors such as obesity and smoking further drives the importance of addressing this condition within the healthcare framework. The rising awareness around early detection and management of varying stages of AMD is anticipated to contribute significantly to the growth of the China Dry Age-Related Macular Degeneration (AMD) Market, reflecting a crucial area of interest for industry stakeholders.The complexity of managing these diverse stages presents opportunities for innovative solutions aimed at minimizing the burden of this chronic condition and enhancing the quality of life for the affected individuals.  Thus, understanding the nuanced characteristics of each stage within Dry AMD is essential for delineating market trends and fortifying approaches tailored to the needs of China's aging population. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Dry Age-Related Macular Degeneration (AMD) Market Age Group Insights** The China Dry Age-Related Macular Degeneration (AMD) Market showcases significant segmentation by age group, reflecting the critical demographics influenced by this condition. The elderly population, particularly those above 75 years, represents a substantial portion of the affected demographic, owing to the natural progression of age-related health issues. This age group often experiences heightened exposure to health risks that lead to the development of AMD, thus creating a significant demand for treatment and management solutions.  Meanwhile, individuals above 60 years are witnessing increasing incidences of AMD as longevity improves, further driving the need for adequate healthcare resources and awareness.Additionally, the group above 40 years is emerging as a focal point of concern, as early signs of AMD can manifest, stressing the importance of early detection and preventive measures. The growth drivers in these segments include an aging population, enhanced healthcare accessibility, and advancement in diagnostic technologies. Challenges arise from the need for tailored treatment approaches to cater to diverse age-related health statuses.  This multifaceted approach to market segmentation underscores the market's evolution in addressing AMD across different age demographics, aligning efforts to improve patient outcomes and awareness in China’s healthcare landscape. **Dry Age-Related Macular Degeneration (AMD) Market Diagnosis and Treatment Insights** The Diagnosis and Treatment segment of the China Dry Age-Related Macular Degeneration (AMD) Market plays a crucial role in mitigating the effects of the disease that significantly impacts the aging population. As the prevalence of AMD rises in China due to an increasingly aging demographic, the demand for effective diagnostic tools and innovative treatment options is on the rise. The growing awareness about early detection and management of AMD has driven improvements in diagnostic technologies, allowing for timely interventions that can enhance the quality of life of patients.Treatments mainly focus on slowing disease progression and improving retinal health, which is essential given the potential vision impairment associated with AMD.  Furthermore, the expanse of the healthcare ecosystem in China is seeing significant investments directed towards advancements in both diagnosis and treatment methods, aligning with the global trend towards innovation in ophthalmology. This focus not only addresses the current healthcare needs but also aims to improve patient outcomes in a market expected to grow substantially as China navigates its demographic shifts.The integration of digital health technologies also represents an opportunity for enhancing patient management and outcomes within this segment. **Dry Age-Related Macular Degeneration (AMD) Market Route of Administration Insights** The Route of Administration segment within the China Dry Age-Related Macular Degeneration (AMD) Market plays a crucial role in the overall management and treatment of this condition. This market segment is primarily characterized by two main forms: oral formulations and injectables. Oral medications offer a convenient method for patients, facilitating easier ingestion, which is especially beneficial in a country like China, where a significant elderly population is prevalent. In contrast, injectables are increasingly significant as they often provide more direct and immediate therapeutic effects, particularly in severe cases of AMD.As healthcare infrastructure improves in urban centers across China, the integration of advanced injectable therapies is expected to gain momentum, thereby addressing varying degrees of disease severity effectively.  The trend is driven by the increasing prevalence of AMD due to an aging population and lifestyle factors, leading to a growing demand for effective treatment options. Opportunities in research and development for delivering more targeted therapies through both routes are on the rise, reflecting a shift toward precision medicine. However, challenges such as the need for skilled personnel to administer injectables and patient adherence to oral medications remain crucial considerations in realizing market potential in both pathways. **Dry Age-Related Macular Degeneration (AMD) Market End Users Insights** The End Users segment of the China Dry Age-Related Macular Degeneration (AMD) Market plays a critical role in addressing the growing needs of the population affected by AMD. As the prevalence of age-related eye conditions rises, hospitals clinics have become pivotal in providing essential diagnosis and treatment services. These facilities often have advanced medical technologies and personnel trained in retinal care, facilitating increased patient access to necessary therapies. Diagnostic centers are also crucial, offering specialized services that ensure early detection and accurate assessments, thus contributing significantly to managing AMD.Moreover, academic research institutes are instrumental in developing innovative treatments and conducting studies that advance the understanding of AMD. Their findings are frequently disseminated, aiding healthcare providers in improving care protocols. The collaboration among these various end users not only enhances patient outcomes but also ensures a more integrated healthcare approach to managing dry AMD in China, reflecting the market's dynamic growth and response to evolving healthcare demands. **China Dry Age-Related Macular Degeneration (AMD) Market Key Players and Competitive Insights** The China Dry Age-Related Macular Degeneration (AMD) Market is rapidly evolving, influenced by various factors such as an aging population, increasing healthcare expenditure, and advancements in medical technology. Competitive insights in this market indicate a diverse landscape comprising both local and international players striving to capture market share with innovative treatment options for AMD. The market dynamics are characterized by a focus on drug development, clinical research, and regulatory approvals, all of which determine market positioning and competitiveness.  Strategic partnerships and collaborations are becoming more common as companies look to leverage technological advancements and combine expertise in developing effective solutions for patients suffering from AMD. Understanding these competitive forces is crucial for companies aiming to establish a robust presence within the Chinese market.Bayer stands out as a key player in the China Dry Age-Related Macular Degeneration (AMD) Market, leveraging its extensive experience in the pharmaceutical sector.  The company has established a strong market presence through its commitment to research and development, resulting in a portfolio of products that address the needs of AMD patients. Bayer's strengths include its robust distribution channels, strong brand reputation, and strategic partnerships that enhance its capability to deliver effective treatments to the Chinese market.  Furthermore, Bayer has invested significantly in raising awareness and educating healthcare providers about AMD, which contributes to its competitive edge and positions the company favorably in a growing market.Horizon Therapeutics has also made significant inroads into the China Dry Age-Related Macular Degeneration (AMD) Market, focusing on innovative therapies that cater specifically to the needs of AMD patients. The company is known for its commitment to research and development and offers key products tailored to combat the challenges posed by dry AMD. With a growing market presence, Horizon Therapeutics is characterized by its strategic collaborations aimed at expanding its reach and enhancing its therapeutic offerings.  The company has engaged in mergers and acquisitions to strengthen its portfolio and enhance its competencies. Horizon Therapeutics’ strengths lie in its ability to adapt to the unique requirements of the Chinese healthcare system while actively promoting education and awareness initiatives to further solidify its position in the China AMD market. **Key Companies in the China Dry Age-Related Macular Degeneration (AMD) Market Include:** - Bayer - Horizon Therapeutics - Zymeworks - Ginkgo BioWorks - Valeant Pharmaceuticals - Bristol-Myers Squibb - Roche - Athenex - Alcon - Pfizer - Novartis - Santen Pharmaceutical - Eyenovia - Regeneron Pharmaceuticals **China Dry Age-Related Macular Degeneration (AMD) Market Industry Developments** In recent months, the China Dry Age-Related Macular Degeneration (AMD) Market has witnessed significant developments, particularly in advancements in treatment and drug approvals. Notably, companies like Regeneron Pharmaceuticals have been focusing on enhancing their product portfolios aimed at managing AMD, which remains a growing concern due to China's aging population. The market has been bolstered by new studies and clinical trials demonstrating the effectiveness of novel therapies.  Furthermore, mergers and acquisitions have been a notable trend; for example, in August 2023, Bayer acquired a Chinese biotech firm specializing in retinal diseases, which aims to strengthen its foothold in the AMD sector. Growth in the market valuation has been increasingly influenced by heightened competition among major players such as Roche, Novartis, and Alcon, all actively engaging in innovative treatment research.  The regulatory environment in China has also evolved, with the National Medical Products Administration accelerating the approval process for AMD treatments. This has fostered a more dynamic market landscape, enhancing accessibility for patients facing AMD. In the past two years, significant funding initiatives by the Chinese government to combat visual impairment diseases have further driven market expansion and research investment. **China Dry Age-Related Macular Degeneration (AMD) Market Segmentation Insights** ## Market Drivers ### Rising Prevalence of Dry AMD The China Dry [Age Related Macular Degeneration](https://www.marketresearchfuture.com/reports/age-related-macular-degeneration-market-5736) Amd Market is experiencing a notable increase in the prevalence of dry AMD, primarily due to the aging population. As of 2025, it is estimated that approximately 200 million individuals globally are affected by AMD, with a significant portion residing in China. This demographic shift is expected to drive demand for diagnostic and therapeutic solutions tailored to dry AMD. Furthermore, the growing awareness of eye health among the elderly population is likely to contribute to increased screening and early detection efforts. Consequently, healthcare providers are focusing on developing targeted interventions to address this rising prevalence, thereby expanding the market for dry AMD treatments in China. ### Rising Awareness and Education The growing awareness and education regarding dry AMD among the Chinese population is significantly influencing the China Dry Age Related Macular Degeneration Amd Market. Public health campaigns and educational programs are increasingly focusing on the importance of eye health, particularly for the aging demographic. As individuals become more informed about the risk factors and symptoms associated with dry AMD, there is a greater likelihood of early detection and treatment. This heightened awareness is expected to drive demand for screening services and therapeutic interventions. Consequently, healthcare providers are likely to respond by expanding their offerings in the dry AMD market, thereby contributing to overall market growth. ### Increasing Healthcare Expenditure The rising healthcare expenditure in China is a crucial driver for the China Dry Age Related Macular Degeneration Amd Market. As the government allocates more resources to healthcare, there is a corresponding increase in funding for eye care services and treatments. In 2025, healthcare spending in China is projected to reach over 10% of GDP, reflecting a commitment to improving health outcomes. This increase in expenditure is likely to facilitate access to advanced diagnostic tools and treatment options for dry AMD, thereby enhancing patient care. Furthermore, the growing middle class in China is expected to demand higher-quality healthcare services, further propelling the market for dry AMD treatments. ### Government Initiatives and Support The Chinese government has been actively promoting initiatives aimed at enhancing eye health, which directly impacts the China Dry Age Related Macular Degeneration Amd Market. Policies such as the Healthy China 2030 initiative emphasize the importance of preventing and managing chronic diseases, including AMD. This governmental support is likely to lead to increased funding for research and development of new treatment modalities. Additionally, public health campaigns aimed at educating the population about the risks associated with AMD are expected to foster greater awareness and early intervention. As a result, the market is poised for growth, driven by both policy support and increased public engagement in eye health. ### Technological Advancements in Treatment The China Dry Age Related Macular Degeneration Amd Market is witnessing rapid technological advancements that are transforming treatment options for patients. Innovations such as gene therapy, stem cell therapy, and advanced imaging techniques are emerging as potential game-changers in the management of dry AMD. For instance, the introduction of novel drug delivery systems is enhancing the efficacy of existing treatments. Moreover, the integration of artificial intelligence in diagnostic processes is improving the accuracy of AMD detection. These advancements not only promise better patient outcomes but also stimulate market growth by attracting investments in research and development. As technology continues to evolve, the market is likely to expand, offering new hope for patients suffering from dry AMD. ## Future Outlook The China Dry Age Related Macular Degeneration AMD Market is projected to grow at a 7.52% CAGR from 2025 to 2035, driven by increasing aging population and advancements in treatment options. **New opportunities:** - Development of telemedicine platforms for remote patient monitoring. - Investment in AI-driven diagnostic tools for early detection. - Expansion of personalized treatment plans based on genetic profiling. By 2035, the market is expected to be robust, reflecting significant advancements and increased accessibility. ## Segment Insights ### By Application: Patient Monitoring (Largest) vs. Therapeutic Intervention (Fastest-Growing) In the China Dry Age Related Macular Degeneration (AMD) market, the 'Application' segment shows a diverse distribution among its key areas. Clinical Diagnosis holds substantial market presence, primarily driven by an increasing incidence of AMD and the rising awareness regarding early detection methods. Research and Development also plays a significant role as it enables innovation in treatment approaches, shaping the market landscape. Despite these strong areas, Patient Monitoring emerges as the largest segment, showcasing its critical role in ongoing patient care, while Therapeutic Intervention is identified as the fastest-growing segment due to advancements in treatment options. Patient Monitoring: Dominant vs. Therapeutic Intervention: Emerging Patient Monitoring serves as the dominant application within the China Dry AMD market, focusing on continuous evaluation of patients' visual health and treatment efficacy. This segment relies on advanced technologies, including digital monitoring tools that facilitate real-time data collection and enhance patient engagement. On the other hand, Therapeutic Intervention is recognized as the emerging segment, driven by a surge in innovative therapies and novel treatment strategies. As new drugs and procedures receive approval and enter the market, this application is set to expand rapidly, presenting promising opportunities for both manufacturers and healthcare providers to improve patient outcomes. ### By End User: Hospitals (Largest) vs. Ophthalmology Clinics (Fastest-Growing) In the China Dry Age Related Macular Degeneration AMD market, hospitals are the largest segment, commanding a significant share due to their comprehensive healthcare services, advanced technologies, and collaboration with specialists. As primary healthcare providers, hospitals play a crucial role in diagnosing and treating AMD, contributing to their substantial market presence. Conversely, ophthalmology clinics are emerging rapidly as pivotal players, benefiting from increased patient awareness, specialized staff, and the ability to provide tailored care that focuses solely on eye health, leading to their rapid growth in the market. Hospitals (Dominant) vs. Ophthalmology Clinics (Emerging) Hospitals are the dominant force in the China Dry Age Related Macular Degeneration AMD market, equipped with the latest diagnostic and treatment technologies and offering a wide range of services, including surgeries and inpatient care. They cater to a diverse patient population, enabling them to handle complex cases and facilitate research and training. On the other hand, ophthalmology clinics are emerging as specialized care centers, focusing exclusively on eye disorders like AMD. These clinics provide personalized services, shorter wait times, and a more intimate healthcare experience. The increasing demand for specialized eye care is propelling their growth, as patients seek dedicated solutions for vision-related issues. ### By Product Type: Diagnostic Devices (Largest) vs. Therapeutic Devices (Fastest-Growing) In the China Dry Age Related Macular Degeneration (AMD) market, the segment for Diagnostic Devices holds a significant market share, emerging as the largest segment due to the rising prevalence of AMD and the growing importance of early detection. Diagnostic Devices encompass a range of tools utilized for accurate imaging and assessment, which are essential in managing AMD effectively. On the other hand, Therapeutic Devices, while smaller in market share, are observing robust growth as advancements in treatment methodologies gain traction. Market Dynamics: Diagnostic Devices (Dominant) vs. Therapeutic Devices (Emerging) Diagnostic Devices currently dominate the market with established technologies that are essential for confirming AMD diagnoses. These devices include Optical Coherence Tomography (OCT) and fundus cameras, which are integral for monitoring disease progression. In contrast, Therapeutic Devices are emerging as a significant growth area, fuelled by innovative treatment solutions, including intravitreal injections and novel therapies aimed at slowing degeneration. The increasing focus on patient-centered care and the development of user-friendly therapeutic solutions are key factors contributing to the growth of this segment, making it an area of interest for manufacturers and healthcare providers. ### By Technology: Optical Coherence Tomography (Largest) vs. Laser Treatment (Fastest-Growing) In the China Dry Age Related Macular Degeneration (AMD) market, technology plays a pivotal role in diagnosis and treatment. Optical Coherence Tomography (OCT) holds the largest share among the technological solutions due to its advanced imaging capabilities which allow for detailed retinal analysis. Fundus Photography and Fluorescein Angiography are also significant, yet their market presence is overshadowed by OCT. Laser Treatment emerges as a novel approach, carving out a growing segment thanks to its non-invasive nature and effectiveness in managing AMD. Technology: Fundus Photography (Dominant) vs. Fluorescein Angiography (Emerging) Fundus Photography remains a dominant technology in the diagnosis and monitoring of Dry AMD given its reliability and widespread acceptance among practitioners. It provides crucial visual records that are valuable for tracking disease progression. In contrast, Fluorescein Angiography is an emerging technology that enhances the understanding of retinal blood flow and is increasingly sought after for its detailed capillary imaging. While Fundus Photography is established, the agility and precision of Fluorescein Angiography position it as a critical tool for future developments in AMD management. ## Competitive Benchmarking The Dry Age Related Macular Degeneration Amd Market in China is characterized by a competitive landscape that is increasingly shaped by innovation and strategic partnerships. Key players such as Novartis (CH), Roche (CH), and Regeneron Pharmaceuticals (US) are actively pursuing strategies that emphasize research and development, aiming to enhance their product offerings and market share. Novartis (CH) has focused on expanding its portfolio through innovative therapies, while Roche (CH) has been investing in digital health solutions to improve patient outcomes. Regeneron Pharmaceuticals (US) appears to be leveraging its strong pipeline of treatments to solidify its position in the market, indicating a trend towards a more integrated approach to AMD management. The market structure is moderately fragmented, with several players vying for dominance. Companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. This trend is particularly evident among domestic players like Hua Medicine (CN) and Chongqing Zhifei Biological Products (CN), who are adapting their operations to meet local demand while also competing with established international firms. The collective influence of these key players is shaping a competitive environment that encourages innovation and responsiveness to market needs. In December 2025, Novartis (CH) announced a strategic partnership with a leading Chinese biotech firm to co-develop a novel [gene therapy](https://www.marketresearchfuture.com/reports/gene-therapy-market-8399) for AMD. This collaboration is expected to accelerate the development of cutting-edge treatments tailored to the Chinese population, highlighting Novartis's commitment to innovation and local market adaptation. Such partnerships may enhance the company's competitive edge by leveraging local expertise and resources. In November 2025, Roche (CH) launched a new digital platform aimed at improving patient engagement and treatment adherence for AMD patients. This initiative underscores Roche's focus on integrating technology into healthcare solutions, potentially transforming how patients interact with their treatment regimens. By enhancing patient support, Roche may strengthen its market position and foster loyalty among healthcare providers. In January 2026, Regeneron Pharmaceuticals (US) reported promising results from a clinical trial for its latest AMD treatment, which demonstrated significant improvements in visual acuity. This development not only reinforces Regeneron's reputation for innovation but also positions the company favorably against competitors. The positive trial outcomes could lead to expedited regulatory approvals, further solidifying its market presence. As of January 2026, the competitive trends in the Dry Age Related Macular Degeneration Amd Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation. The shift from price-based competition to a focus on technological advancements and supply chain reliability is evident, suggesting that future competitive differentiation will hinge on the ability to deliver innovative solutions that meet evolving patient needs. ## Recent News & Developments In recent months, the China Dry Age-Related Macular Degeneration (AMD) Market has witnessed significant developments, particularly in advancements in treatment and drug approvals. Notably, companies like Regeneron Pharmaceuticals have been focusing on enhancing their product portfolios aimed at managing AMD, which remains a growing concern due to China's aging population. The market has been bolstered by new studies and clinical trials demonstrating the effectiveness of novel therapies.  Furthermore, mergers and acquisitions have been a notable trend; for example, in August 2023, Bayer acquired a Chinese biotech firm specializing in retinal diseases, which aims to strengthen its foothold in the AMD sector. Growth in the market valuation has been increasingly influenced by heightened competition among major players such as Roche, Novartis, and Alcon, all actively engaging in innovative treatment research.  The regulatory environment in China has also evolved, with the National Medical Products Administration accelerating the approval process for AMD treatments. This has fostered a more dynamic market landscape, enhancing accessibility for patients facing AMD. In the past two years, significant funding initiatives by the Chinese government to combat visual impairment diseases have further driven market expansion and research investment. ## Report Scope | MARKET SIZE 2024 | 357.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 386.62(USD Million) | | MARKET SIZE 2035 | 792.75(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.52% (2024 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Novartis (CH), Roche (CH), Regeneron Pharmaceuticals (US), Bayer (DE), Allergan (IE), Santen Pharmaceutical (JP), Hua Medicine (CN), Chongqing Zhifei Biological Products (CN) | | Segments Covered | Application, End User, Product Type, Technology | | Key Market Opportunities | Emerging telemedicine solutions enhance access to treatments in the China Dry Age Related Macular Degeneration Amd Market. | | Key Market Dynamics | Rising prevalence of Dry Age Related Macular Degeneration in China drives demand for innovative treatment solutions and technologies. | | Countries Covered | China | ## Frequently Asked Questions **Q: What is the current valuation of the China Dry Age Related Macular Degeneration Amd Market?** A: The market valuation was 357.0 USD Million in 2024. **Q: What is the projected market size for the China Dry Age Related Macular Degeneration Amd Market by 2035?** A: The projected valuation for 2035 is 792.75 USD Million. **Q: What is the expected CAGR for the China Dry Age Related Macular Degeneration Amd Market during the forecast period?** A: The expected CAGR for the market from 2025 to 2035 is 7.52%. **Q: Which companies are the key players in the China Dry Age Related Macular Degeneration Amd Market?** A: Key players include Novartis, Roche, Regeneron Pharmaceuticals, Bayer, Allergan, Santen Pharmaceutical, Hua Medicine, and Chongqing Zhifei Biological Products. **Q: What are the main application segments in the China Dry Age Related Macular Degeneration Amd Market?** A: Main application segments include Clinical Diagnosis, Research and Development, Patient Monitoring, and Therapeutic Intervention. **Q: How much revenue did the Therapeutic Intervention segment generate in 2024?** A: The Therapeutic Intervention segment generated 142.0 USD Million in 2024. **Q: What is the revenue range for the Patient Monitoring segment projected for 2025?** A: The Patient Monitoring segment is projected to generate between 60.0 and 120.0 USD Million. **Q: Which end-user segment is expected to have the highest revenue in the China Dry Age Related Macular Degeneration Amd Market?** A: The Hospitals segment is expected to generate between 100.0 and 230.0 USD Million. **Q: What types of products are included in the China Dry Age Related Macular Degeneration Amd Market?** A: Product types include Diagnostic Devices, Therapeutic Devices, Monitoring Devices, and Surgical Instruments. **Q: What technologies are utilized in the China Dry Age Related Macular Degeneration Amd Market?** A: Technologies include Optical Coherence Tomography, Fundus Photography, Fluorescein Angiography, and Laser Treatment. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/china-dry-age-related-macular-degeneration-market-44901*